August 2013 Br J Cardiol 2013;20:92-93 Online First
BJCardio Staff
Data on the trends in management of patients with AF in five European countries were presented in a Late Breaking Clinical Trials session at the meeting. PREFER AF (Prevention of Thromboembolic Events –European Registry in Atrial Fibrillation) found that oral anticoagulation is now used in over 85% of patients with AF eligible for therapy. PREFER AF provides a ‘snapshot’ of clinical practice across five European countries taken in 2012. It revealed that NOACs are now used by 6.1% of AF patients and that use of rhythm control interventions and catheter ablations have increased. “PREFER AF illustrates changes in management of patients w
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits